CONTINUUS Pharmaceuticals

About

CONTINUUS Pharmaceuticals, based in Woburn, Massachusetts, specializes in Integrated Continuous Manufacturing (ICM) solutions for small-molecule pharmaceuticals. Founded in 2012 as a spin-out from a collaboration between MIT and Novartis, the company focuses on replacing traditional batch processes with efficient, continuous operations. Their end-to-end ICM platforms integrate the synthesis of active pharmaceutical ingredients (APIs) with final dosage form production, significantly reducing production timelines and enhancing quality and cost-effectiveness. The company offers comprehensive ICM solutions, including process development, optimization, and manufacturing platforms that streamline the production of pharmaceuticals. Their innovative technologies, such as continuous flow chemistry and real-time monitoring, support rapid scaling and improved environmental safety. CONTINUUS aims to bring pharmaceutical manufacturing back to the U.S. and supports the production of generics, specialized drugs, and essential medicines. With a recent $69.3M U.S. government contract, CONTINUUS is positioned to play a vital role in addressing drug shortages and enhancing global affordability.